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Despite the great advances that have been made over the last 20 years in its early 
detection and treatment, breast cancer remains one of the most frequently diagnosed 
malignancy and a leading cause of cancer-related deaths in women worldwide. Since 
the majority of breast cancer deaths occurs as a result of metastasis rather than from the 
effects of the primary lesion, markers useful to predict breast cancer evolution from car-
cinoma in situ to invasive tumor are crucial for the management of patients with breast 
diseases. Although several features have been recognized as having prognostic use in 
invasive tumors, at present, no marker has been clearly associated with the progression 
of breast lesions from in situ to invasive. 
Among the intracellular signal transduction molecules, the phosphoinositide-de-
pendent phospholipases C (PI-PLCs) are involved in malignant features of a wide va-
riety of tissues, including breast. In particular, the expression of the beta2 isozyme in 
primary breast tumors positively correlates with the de-differentiation levels of malig-
nant cells, with biological and clinical-pathological factors currently used to characterize 
invasive breast carcinomas and with a poor prognosis of breast tumor patients. 
Based on the above reported considerations, we tried to elucidate whether PI-PLC 
beta2 expression could be involved in the switchover of breast tumors from in situ to 
invasive. With this intent, we have performed a retrospective analysis of PI-PLC beta2 
expression in sample tissues from breast lesions, including in situ and invasive carci-
nomas, correlating the levels of PI-PLC beta2 with the most common histological and 
biological prognostic and predictive parameters for breast tumors. 
The obtained data indicate that the expression of PI-PLC beta2 characterizes the tran-
sition of the mammary tissue from normal to tumoral but not the evolution of breast 
cancer from in situ to invasive. In addition, PI-PLC beta2 amount in invasive breast tu-
mors positively correlates with their malignant properties. Finally, in ductal carcinoma 
in situ, the in situ breast cancer more frequently detected and that more often progresses 
to invasive, we have demonstrated the existence of sub-populations of cells expressing 
different PI-PLC beta2 amounts, possibly with a diverse functional meaning.
If it is true that most breast cancers evolve from precursors which gradually change 
over time, the identification of biological alterations associated with early lesions, before 
the development of invasion/metastasis-related features, may pave the way for design-
ing strategies for the treatment of the majority of breast cancers and could provide im-
portant contributions in predicting the clinical course of individual patients. 
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